Dianthus Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $761 | $463 | $284 | $396 |
Gross Profit | 761 | 387 | 284 | 396 |
EBITDA | -50,178 | -40,758 | 98,164 | -36,738 |
EBIT | -50,215 | -40,834 | 97,905 | -36,765 |
Net Income | -50,215 | -40,834 | 97,905 | -36,765 |
Net Change In Cash | 761 | 463 | 284 | 396 |
Free Cash Flow | -49,162 | -28,866 | -47,121 | -30,560 |
Cash | 110,549 | 627,667 | 51,087 | 55,984 |
Basic Shares | 56,029 | 48,032 | 37,794 | 37,794 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $2,036 | $6,235 | $2,826 | $6,417 |
Gross Profit | 2,036 | 6,235 | 2,826 | 6,417 |
EBITDA | -161,909 | -84,557 | -43,200 | -28,329 |
EBIT | -162,337 | -84,969 | -43,555 | -28,476 |
Net Income | -162,337 | -84,969 | -43,555 | -28,476 |
Net Change In Cash | 2,036 | 6,235 | 2,826 | 6,417 |
Free Cash Flow | -129,273 | -78,285 | -36,971 | -29,209 |
Cash | 51,087 | 22,792 | 132,325 | 15,365 |
Basic Shares | 37,794 | 33,314 | 5,153 | 3,747 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.90 |
2026-03-31 | -$0.85 |
2025-12-31 | -$1.43 |
2025-09-30 | -$0.97 |